

Title (en)
METHOD

Title (de)
VERFAHREN ZUR HERSTELLUNG

Title (fr)
PROCEDE

Publication
EP 0930897 A2 19990728 (EN)

Application
EP 97934621 A 19970730

Priority
• GB 9702072 W 19970730
• GB 9619759 A 19960923

Abstract (en)
[origin: WO9811921A2] The invention provides the use of a physiologically tolerable manganese compound or a salt thereof, substantially free from hydrophilic polymer components containing a significant amount of a Mn<2+>- chelating unit, in the manufacture of an enterally, e.g. orally or rectally, administrable MRI contrast medium composition for use in a method of imaging of a human or non-human animal body which has fasted for a period of at least 6, preferably at least 10, more preferably at least 12 hours before enteral administration of said composition. It has been found that diagnostically effective levels of uptake of orally or rectally administered manganese may be achieved using this method.

IPC 1-7
A61K 49/00

IPC 8 full level
A61K 49/00 (2006.01); **A61K 49/06** (2006.01); **A61K 49/18** (2006.01)

CPC (source: EP)
A61K 49/06 (2013.01); **A61K 49/18** (2013.01)

Citation (search report)
See references of WO 9811921A2

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9811921 A2 19980326; **WO 9811921 A3 19980813**; AU 3776697 A 19980414; CA 2265856 A1 19980326; CN 1238698 A 19991215; EP 0930897 A2 19990728; GB 9619759 D0 19961106; JP 2001500870 A 20010123

DOCDB simple family (application)
GB 9702072 W 19970730; AU 3776697 A 19970730; CA 2265856 A 19970730; CN 97180009 A 19970730; EP 97934621 A 19970730; GB 9619759 A 19960923; JP 51436598 A 19970730